Eterna Therapeutics (ERNA) Stock Price, News & Analysis

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.25 to $0.26
• 50-Day Range: $0.26 to $0.64
• 52-Week Range: $0.22 to $2.63
• Volume: 97,331 shs
• Average Volume: 13.32 million shs
• Market Capitalization: $1.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Eterna Therapeutics Stock Analysis - MarketRank™

Eterna Therapeutics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Eterna Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eterna Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eterna Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.80% of the float of Eterna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Eterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eterna Therapeutics has recently increased by 86.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eterna Therapeutics does not currently pay a dividend.

Dividend Growth

Eterna Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.80% of the float of Eterna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Eterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eterna Therapeutics has recently increased by 86.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.44

News Sentiment

Eterna Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ERNA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.49% of the stock of Eterna Therapeutics is held by insiders.

Percentage Held by Institutions

70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ERNA Stock Analysis - Frequently Asked Questions

How have ERNA shares performed this year?

Eterna Therapeutics' stock was trading at $0.2940 at the beginning of the year. Since then, ERNA stock has decreased by 13.3% and is now trading at $0.2550.
View the best growth stocks for 2025 here.

How were Eterna Therapeutics' earnings last quarter?

Eterna Therapeutics Inc. (NASDAQ:ERNA) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($4.92) earnings per share (EPS) for the quarter. The firm earned $0.49 million during the quarter.

Who are Eterna Therapeutics' major shareholders?

Eterna Therapeutics' top institutional shareholders include Geode Capital Management LLC (4.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends.

How do I buy shares of Eterna Therapeutics?

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eterna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 3/13/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ERNA
• CIK: 748592
• Web: www.brooklynitx.com
• Phone: (212) 582-1199
• Fax: 760-438-3505
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($8.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,670,000.00
• Net Margins: -7,513.88%
• Pretax Margin: -7,511.37%
• Return on Equity: N/A
• Return on Assets: -117.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.48
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: $598,000.00
• Price / Sales: 2.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 5,411,000
• Free Float: 5,168,000
• Market Cap: $1.38 million
• Optionable: No Data
• Beta: 4.47